WuXi Biologics (Cayman) revenue and financials
$56.70Change from previous close: −2.07%Absolute change: −$1.20
In the fiscal year ended December 2025, WuXi Biologics (Cayman) reported revenue of ¥21.79B (+16.68% year over year). Net income was ¥4.91B, a net margin of 22.5%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +16.68%
- 2025 vs 2024
- Net income growth
- +46.25%
- 2025 vs 2024
- Net margin
- 22.5%
- 2024: 18.0%
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | Q2 2026 | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 4,287 | 4,534 | 1,807 | 3,915 | 1,302 | 1,918 | 2,750 | 4,084 | 1,458 | 2,633 |
| Depreciation and amortization | 937 | 594 | 854 | 613 | 824 | 501 | 668 | 300 | 501 | 150 |
| Capital expenditure | -2,757 | -1,785 | -1,900 | -2,062 | -1,867 | -1,664 | -2,381 | -3,184 | -2,685 | -2,435 |
| Investing cash flow | -2,138 | -2,549 | -538 | -3,559 | -383 | -1,639 | -1,589 | -3,545 | -2,363 | -1,860 |
| Financing cash flow | -2,111 | -1,078 | -1,086 | -1,275 | -1,476 | 2,149 | -188 | -2,373 | -219 | -3,006 |
| Share repurchases | -1,021 | -545 | -1,032 | -532 | -1,234 | -917 | — | -2,113 | -691 | -2,517 |
| Debt issued | 95.0 | 160 | 962 | 762 | 367 | 319 | 779 | 1,975 | 414 | 25.0 |
| Debt repaid | -911 | -1,941 | -960 | -382 | -436 | -1,014 | -901 | -2,259 | -425 | -499 |
| Effect of exchange rates | -302 | -132 | -23.1 | 44.3 | 39.7 | -113 | -13.0 | 94.3 | 256 | -45.3 |
| Net change in cash | -264 | 775 | 160 | -874 | -516 | 2,315 | 960 | -1,740 | -868 | -2,278 |
| Free cash flow | 1,530 | 2,749 | -93.7 | 1,853 | -565 | 253 | 369 | 900 | -1,227 | 199 |
| Levered free cash flow | -333 | 2,753 | 1,531 | -1,523 | -774 | -169 | -151 | 1,348 | -1,943 | 625 |